Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech is progressing towards its proposed privatization by Fosun New Medicine through a merger, having recently fulfilled all necessary pre-conditions. This strategic move is expected to streamline operations and potentially enhance shareholder value. The despatch of related documents to shareholders is anticipated by December 2024.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.